THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal™, an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonstrates non-inferiority in all the endpoints of the study, compared to Androgel®, a cream which is the leading treatment for low testosterone.
